Our monthly portfolio positioning commentary.
The pandemic took a turn for the worse over Q4 as new infection rates rose significantly. However, concerns over the rising infections were overshadowed by the US election result and announcements regarding the approval and efficacy of vaccines.
Global equities posted the largest one-month gain since 2008 following the news of positive trial results of several COVID-19 vaccines. Furthermore, the vaccine developed by Pfizer and BioNTech was found to be more than 90% effective.
Despite many leading economic indicators suggesting that global trade has returned to an upward trajectory in October, after the steep drops in May and June, only the MSCI Emerging Markets and CSI China Securities 300 indices (from the worlds main stock markets) provided positive returns during October, returning 2.04% and 4.05% respectively.
The post Covid-19 economic recovery appears a little uneven across the world. Recent US economic data has been very positive, whereas activity in the UK, where Brexit is looming, is not as positive.
Optimism continued to rise in August amid mounting hopes for a COVID-19 vaccine and solid global growth.
In equity markets, better economic activity data pushed prices higher, albeit for U.K. Sterling based investors most international equity markets ended the month in negative territory as the U.S. Dollar weakened.